Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a sublingual tablet repair the Brain's leaky barrier in CADASIL?

NCT ID NCT07692399

Not yet recruiting Disease control Sponsor: Huashan Hospital Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial investigates whether edaravone dexborneol sublingual tablets can improve blood-brain barrier function in people with CADASIL, a genetic condition that causes small strokes and cognitive decline. About 60 adults aged 18 to 80 with confirmed CADASIL will be observed for 6 months without the drug, then take the tablet twice daily for another 6 months. The study measures changes in brain barrier health using MRI and tracks stroke events, thinking skills, and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
edaravone dexborneol sublingual tablets
What this could lead to
If it works, this could point toward a treatment that slows brain damage and lowers stroke risk in people with CADASIL.
What could go wrong
This is a small, early-phase trial with no placebo group, so results may not be conclusive. The drug may not improve outcomes or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CADASIL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral arteriopathy with subcortical infarcts and leukoencephalopathy cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CADASIL

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Huashan Hospital, Fudan University

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.